USCWA
BNGO icon

U.S. Capital Wealth Advisors’s Bionano Genomics BNGO Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17
Closed -$55K – 720
2021
Q3 		$55K Buy
+17
New +$59.5K ﹤0.01% 710

Other funds holding BNGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

U.S. Capital Wealth Advisors's BNGO Position: Q4 2021 in Review

U.S. Capital Wealth Advisors sold out of Bionano Genomics (BNGO) in Q4 2021, closing a stake of 17 shares — an estimated $55K sold.

U.S. Capital Wealth Advisors first reported a position in BNGO in Q3 2021 and held it in 1 quarter. The position peaked at $55K in Q3 2021. 149 funds tracked by Wall St. Rank hold BNGO as of Q4 2021.

  • U.S. Capital Wealth Advisors reported no remaining Bionano Genomics position as of Q4 2021 after selling out during the quarter.
  • U.S. Capital Wealth Advisors sold 17 Bionano Genomics shares in Q4 2021, an estimated $55K.
  • U.S. Capital Wealth Advisors first reported a position in Bionano Genomics in Q3 2021 and held it in 1 quarter.
  • U.S. Capital Wealth Advisors's Bionano Genomics position peaked at $55K in Q3 2021.
  • 149 funds tracked by Wall St. Rank held Bionano Genomics as of Q4 2021.

Based on U.S. Capital Wealth Advisors's 13F filing for Q4 2021, filed 21 Jan 2022.